Therapeutic Drug Monitoring of Mycophenolic Acid

Shaw, Leslie M.; Figurski, Michal; Milone, Michael C.; Trofe, Jennifer; Bloom, Roy D.

doi:10.2215/cjn.03861106

Cited by 76 publications

(50 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The study population presented an equitable gender distribution, aged 40.6 ± 12.5 years, qualified as a young adult study population. According to Shaw et al (2007), therapeutic levels of MPA should range from ≥1.0 to 3.0 μg/mL. In the current study, 46% of patients had plasma levels in this range, and 38.5% of MPA levels were above the therapeutic range.…”

Section: Resultsmentioning

confidence: 45%

See 1 more Smart Citation

Study on the association of UGT1A9 gene c.98T>C polymorphism and mycophenolic acid plasma levels in renal transplant patients

Ruschel

Schmitt

Silva³

et al. 2017

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Mycophenolate mofetil (MMF) is a prodrug active only after its hydrolysis to mycophenolic acid (MPA). The UGT1A9 enzyme is of special interest since it is the main enzyme involved in the glucuronidation of MPA. Single nucleotide polymorphisms (SNPs) in the UGT1A9 gene may be responsible for individual differences in the pharmacokinetics of MMF. Expression levels and the activity of UGT1A9 may depend on the presence of some SNPs located in the gene promoter region (-2152C>T and -275T>A), as well as changes in the coding region (c.98T>C). The objective of this study was to evaluate the effect of allelic variants of the UGT1A9 c.98T>C polymorphism (rs72551330; g. 87289T>C) on MMF metabolism in 2 L.R. Ruschel et al.Genetics and Molecular Research 16 (2): gmr16029598 renal transplant patients. MPA and MPA 7-O glucuronide (MPAG) levels were determined on plasma samples of kidney transplant patients (N = 39) by high-performance liquid chromatography using ultraviolet detection. DNA was isolated from leukocytes and stored at -20°C. The presence of SNPs was investigated using polymerase chain reaction, followed by amplicon sequencing. The analysis of the UGT1A9 c.98T>C polymorphism revealed that all study patients presented the TT genotype. Diverse MPA and MPAG plasma concentrations were detected, including therapeutic, subtherapeutic, and toxic levels. A standardized molecular method permitted identification of UGT1A9 c.98T>C polymorphism genotypes in the examined renal transplant patients. All individuals of the study group presented the same genotype (c.98TT) for that polymorphism. Thereby, no association between the c.98T>C polymorphism and MPA and MPAG plasma levels could be evaluated, despite different levels of these compounds being observed.

show abstract

Section: Resultsmentioning

confidence: 45%

“…It has been known that the most common side effects of MMF therapy are diarrhea and leukopenia, which may reduce treatment adhesion, and significantly compromises patients' life quality (Shaw et al, 2007). Moreover, 15.4% of patients had plasma levels below therapeutic levels, which poses a risk of graft rejection.…”

Section: Discussionmentioning

confidence: 99%

Study on the association of UGT1A9 gene c.98T>C polymorphism and mycophenolic acid plasma levels in renal transplant patients

Ruschel

Schmitt

Silva³

et al. 2017

Genet. Mol. Res.

View full text Add to dashboard Cite

show abstract

“…A proposed schedule for objective assessment of MPA exposure is presented in Table 4. We hope that the ongoing trials will provide more definitive data on which to base the selection of sample type, test schedule, and the costbenefit analysis of MPA therapeutic monitoring (Shaw et al, 2007).…”

Section: Therapeutic Drug Monitoringmentioning

confidence: 99%

Clinical Pharmacokinetics of Triple Immunosuppression Scheme in Kidney Transplant (Tacrolimus, Mycophenolate Mofetil and Corticosteroids)

Luisa¹,

Alejandro²

2011

Understanding the Complexities of Kidney Transplantation

View full text Add to dashboard Cite

“…Le MMF est le morpholinoethylester du MPA, qui est le principe actif. Il est rapidement hydrolysé dans le tube digestif supérieur, pour produire du MPA [15]. Le MPS libère le MPA à un pH neutre dans l'intestin grêle avec de ce fait une absorption plus lente [16].…”

Section: Exemple 2 : Inhibiteur De L'inosine Monophosphate Déshydrogéunclassified

Apports récents de la pharmacologie des traitements immunosuppresseurs utilisés en transplantation d’organe

Thervet

2008

Med Sci (Paris)

View full text Add to dashboard Cite

Therapeutic Drug Monitoring of Mycophenolic Acid

Cited by 76 publications

References 60 publications

Study on the association of UGT1A9 gene c.98T>C polymorphism and mycophenolic acid plasma levels in renal transplant patients

Study on the association of UGT1A9 gene c.98T>C polymorphism and mycophenolic acid plasma levels in renal transplant patients

Clinical Pharmacokinetics of Triple Immunosuppression Scheme in Kidney Transplant (Tacrolimus, Mycophenolate Mofetil and Corticosteroids)

Apports récents de la pharmacologie des traitements immunosuppresseurs utilisés en transplantation d’organe

Contact Info

Product

Resources

About